Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study

被引:0
|
作者
Chen, Ruo-Yang [1 ]
Li, Da -Wei [1 ]
Wang, Jie-Ying [2 ]
Zhuang, Shao-Yong [1 ]
Wu, Hao-Yu [1 ]
Wu, Jia-Jin [1 ]
Qu, Jun-Wen [1 ]
Sun, Nan [1 ]
Zhong, Chen [1 ]
Zhu, Cheng [3 ]
Zhang, Ming [1 ,5 ]
Yu, Yue-Tian [4 ,5 ]
Yuan, Xiao-Dong [1 ,5 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Clin Res Ctr, Sch Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Dis Prevent & Control, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Crit Care Med, Shanghai, Peoples R China
[5] 145 Middle Shandong Rd, Shanghai, Peoples R China
关键词
Trimethoprim-sulfamethoxazole; Kidney transplantation; Pneumocystis jirovecii pneumonia; Fungal infection; Prophylaxis;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate the efficacy and safety of low-dose trimethoprim (TMP)-sulfamethoxazole (SMX) (TMP-SMX) as the primary prophylaxis for Pneumocystis jirovecii pneumonia (PJP) in adult recipients of kidney transplantation.Methods: Three kinds of prescriptions in kidney recipients were documented, including 20 mg TMP/100 mg SMX oral daily, 20 mg TMP/100 mg SMX oral every other day, and nonprophylaxis. The primary outcome was the incidence of PJP in the first 180 days of follow-up after kidney transplantation. The secondary outcomes were changes in renal and liver function.Results: Among the 1469 recipients, 1066 (72.56%) received 20 mg TMP/100 mg SMX daily, 127 (8.65%) received 20 mg TMP/100 mg SMX every other day, and 276 (18.79%) did not have prophylaxis prescrip-tion. The 276 recipients in the nonprophylaxis group had 124.92 person-years of follow-up, during which PJP occurred in 29 patients, for an incidence rate of 23.21 (95% confidence interval 15.76-32.72) per 100 person-years. The TMP-SMX daily group and the TMP-SMX every other day group had 524.89 and 62.07 person-years of follow-up, respectively, with no occurrence of PJP. There was no significant difference among the three groups in changes in renal and liver function ( P > 0.05, respectively). A total of 111 recipients in each group were enrolled in the propensity score matching analysis. It was revealed that the 111 nonprophylaxis recipients had 51.27 person-years of follow-up and 10 PJP cases. Prophylaxis was considered effective because there was a significant difference between the three groups ( P < 0.001).Conclusion: Low-dose TMP-SMX prophylaxis significantly reduces the incidence of PJP within 6 months after kidney transplantation and has a favorable safety profile.& COPY; 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:209 / 215
页数:7
相关论文
共 38 条
  • [31] Effectiveness and Safety Evaluation of Thrice Weekly Double Strength vs Daily Single Strength Trimethoprim-Sulfamethoxazole for Prophylaxis of Pneumocystis Jirovecii Pneumonia after Kidney Transplantation: A Two-Year Prospective Cohort Study
    Yang, Hui
    Pang, Lizhen
    Hu, Xiaopeng
    Wang, Wei
    Xu, Bifang
    Zhang, Xiaodong
    Liu, Lihong
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2021, 24 : 220 - 226
  • [32] Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study
    Nakashima, Kei
    Aoshima, Masahiro
    Nakashita, Tamao
    Hara, Masahiko
    Otsuki, Ayumu
    Noma, Satoshi
    Misawa, Masafumi
    Otsuka, Yoshihito
    Motojima, Shinji
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2018, 51 (06) : 810 - 820
  • [33] Efficacy and safety of a low-dose sulfamethoxazole/trimethoprim regimen in preventing pneumocystis pneumonia: A retrospective study using a large-scale electronic medical record database
    Takeda, Koki
    Okada, Akira
    Sera, Shoji
    Oishi, Teruki
    Nagai, Naomi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [34] Efficacy and safety of low-dose versus conventional-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected patients: A multi-centre, retrospective observational cohort study (RE-VISION-PCP)
    Nagai, Tatsuya
    Fujioka, Haruka
    Homma, Yuya
    Otsuki, Ayumu
    Ito, Hiroyuki
    Nakashima, Kei
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [35] Low-dose aspirin for prevention of cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease: A real-world nationwide cohort study
    Lin, Yi-Cheng
    Chen, Bi-Li
    Chen, Wan-Ting
    Chien, Li-Nien
    Huang, Chun-Yao
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (04) : 459 - 467
  • [36] A REAL-WORLD STUDY OF LENALIDOMIDE COMBINED WITH LOW-DOSE VENECLA IN MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RECURRENT AND REFRACTORY HEMATOLOGICAL MALIGNANCIES
    Li, Zhihui
    Zheng, Qinglong
    Yang, Keyan
    Wang, Xianxuan
    Wu, Fan
    Wen, Xiaopei
    Zhang, Caiyan
    Wu, Tong
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 501 - 501
  • [37] Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD-High Study)
    Trikha, Mehak
    Sarkar, Laboni
    Dhanawat, Aditya
    Syed, Noorzia
    Gujarathi, Himanshu
    Vora, Manan
    Raja, A. Sree Sivakumar
    Bhargava, Prabhat
    Ramaswamy, Anant
    Mandavkar, Sarika
    Saklani, Avanish
    Kaushal, Rajiv Kumar
    Bal, Munita
    Shetty, Omshree
    Yadav, Subhash
    Ostwal, Vikas
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [38] Effectiveness and safety of a fixed, low-dose perindopril/indapamide combination in patients with arterial hypertension: real-world clinical practice data (STRATEGYA, a multi-center, open, prospective study)
    Martynyuk, T. V.
    Kolos, I. P.
    Chazova, I. E.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2007, 6 (08): : 21 - +